Moneycontrol PRO
Upcoming Event:\Option Writing Masterclass by Shubham Agarwal: a session power packed with lots of intelligence and tactics required to sell write options, on 13th July at 5pm. Register Now

Buy Granules India; target of Rs 345: ICICI Direct

ICICI Direct is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 345 in its research report dated May 19, 2022.

May 20, 2022 / 08:09 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Granules India

Granules is a large-scale vertically integrated company that manufactures API, intermediates and finished dosages and has seven manufacturing facilities along with B2B & B2C marketing & distribution. • Revenue mix FY22: Formulations – 52%, API (API+PFI) – 48% • Top five products (Paracetamol, Ibuprofen, Metformin, Methocarbamol, Guaifenesin) contributed 81% to FY22 revenues.


We maintain BUY on the back of 1) launches lined up across geographies along with incremental contribution from MUPS block, 2) focus on backward integration, 3) initiatives like passing on price hike to customers, and 4) compelling risk-reward matrix based on FY24E earnings. Valued at Rs 345 i.e. 14x P/E on FY24E EPS of Rs 24.6


For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: May 20, 2022 08:09 pm
ISO 27001 - BSI Assurance Mark